The effects of anti-inflammatory and anti-angiogenic DNA vaccination on diabetic nephropathy in rats

Human Gene Therapy

Volumn 23, Issue 2, 2012, Pages 158-166

  Celec, Peter ^a   Hodosy, Július ^a   Gardlík, Roman ^a,b   Behuliak, Michal ^a   Pálffy, Roland ^a   Pribula, Marek ^a   Jáni, Peter ^c   Turňa, Ján ^a   Šebeková, Katarína ^a  

^a Physics and Informatics   (Slovakia)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Hospital Krnov   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS MODULATOR; ANGIOMOTIN; COLLAGEN TYPE 1; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PLASMID DNA; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DNA IMMUNIZATION; KIDNEY CORTEX; KIDNEY HYPERTROPHY; MALE; NONHUMAN; PERIODIC ACID SCHIFF STAIN; PROTEIN EXPRESSION; RAT; RENAL PROTECTION; STREPTOZOCIN DIABETES;

ANIMALS; CHEMOKINE CCL2; COLLAGEN; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; ELECTROPORATION; FIBROSIS; GENE EXPRESSION; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERLEUKIN-6; KIDNEY GLOMERULUS; MALE; MEMBRANE PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; PLASMIDS; RATS; RATS, WISTAR; TRANSFORMING GROWTH FACTOR BETA; VACCINATION; VACCINES, DNA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

ANIMALIA; RATTUS;

EID: 84856866155     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2011.030     Document Type: Article

References (68)

1. Awad, A.S., Huang, L.P., Ye, H., et al. (2006). Adenosine A(2A) receptor activation attenuates inflammation and injury in diabetic nephropathy.Am. J. Physiol. Renal Physiol. 290, F828-F837. (Pubitemid 43724943)
2. Banba, N., Nakamura, T., Matsumura, M., et al. (2000). Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy. Kidney Int. 58, 684-690. (Pubitemid 30620017)
3. Barouch, D.H., Santra, S., Schmitz, J.E., et al. (2000). Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 290, 486-492.
4. Benzie, I.F., and Strain, J.J. (1996). The ferric reducing ability of plasma (FRAP) as a measure of "antioxidant power": the FRAP assay. Anal. Biochem. 239, 70-76.
5. Boor, P., Celec, P., Behuliak, M., et al. (2009). Regular moderate exercise reduces advanced glycation and ameliorates early diabetic nephropathy in obese Zucker rats. Metabolism 58, 1669-1677.
6. Buchan, S., Gronevik, E., Mathiesen, I., et al. (2005). Electroporation as a "prime/boost" strategy for naked DNA vaccination against a tumor antigen. J. Immunol. 174, 6292-6298. (Pubitemid 40663821)
7. Cha, D.R., Kang, Y.S., Han, S.Y., et al. (2004). Vascular endothelial growth factor is increased during early stage of diabetic nephropathy in type II diabetic rats. J. Endocrinol. 183, 183-194. (Pubitemid 40124655)
8. Chander, P.N., Gealekman, O., Brodsky, S.V., et al. (2004). Nephropathy in Zucker diabetic fat rat is associated with oxidative and nitrosative stress: prevention by chronic therapy with a peroxynitrite scavenger ebselen. J. Am. Soc. Nephrol. 15, 2391-2403. (Pubitemid 39159339)
9. Chen, S., and Ziyadeh, F.N. (2008). Vascular endothelial growth factor and diabetic nephropathy. Curr. Diabetes Rep. 8, 470-476.
10. Chow, F.Y., Nikolic-Paterson, D.J., Ozols, E., et al. (2006). Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int. 69, 73-80. (Pubitemid 43117741)
11. Cukjati, D., Batiuskaite, D., Andre, F., et al. (2007). Real time electroporation control for accurate and safe in vivo non-viral gene therapy. Bioelectrochemistry 70, 501-507. (Pubitemid 46507981)
12. De Vriese, A., Tilton, R.G., Elger, M., et al. (2001). Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J. Am. Soc. Nephrol. 12, 993-1000. (Pubitemid 32378340)
13. Durieux, A.C., Bonnefoy, R., Busso, T., and Freyssenet, D. (2004). In vivo gene electrotransfer into skeletal muscle: effects of plasmid DNA on the occurrence and extent of muscle damage. J. Gene Med. 6, 809-816. (Pubitemid 40228097)
14. Durieux, A.C., Bonnefoy, R., and Freyssenet, D. (2005). Kinetic of transgene expression after electrotransfer into skeletal muscle: importance of promoter origin/strength. Biochim. Biophys. Acta 1725, 403-409. (Pubitemid 41393536)
15. Egashira, K., Koyanagi, M., Kitamoto, S., et al. (2000). Antimonocyte chemoattractant protein-1 gene therapy inhibits vascular remodeling in rats: blockade of MCP-1 activity after intramuscular transfer of a mutant gene inhibits vascular remodeling induced by chronic blockade of NO synthesis. FASEB J. 14, 1974-1978.
16. Erel, O. (2004). A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clin. Biochem. 37, 277-285. (Pubitemid 38314881)
17. Ferrara, N., and Alitalo, K. (1999). Clinical applications of angiogenic growth factors and their inhibitors. Nat. Med. 5, 1359-1364.
18. Flyvbjerg, A., Dagnaes-Hansen, F., De Vriese, A.S., et al. (2002). Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. Diabetes 51, 3090-3094.
19. Göser, S., Ottl, R., Brodner, A., et al. (2005) Critical role for monocyte chemoattractant protein-1 and macrophage inflammatory protein-1a in induction of experimental autoimmune myocarditis and effective anti-monocyte chemoattractant protein-1 gene therapy. Circulation 112, 3400-3407. (Pubitemid 43739554)
20. Goudy, K.S., Wang, B., and Tisch, R. (2008). Gene gun-mediated DNA vaccination enhances antigen-specific immunotherapy at a late preclinical stage of type 1 diabetes in nonobese diabetic mice. Clin. Immunol. 129, 49-57.
21. Han, S.Y., Kim, C.H., Kim, H.S., et al. (2006). Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. J. Am. Soc. Nephrol. 17, 1362-1372.
22. Herrera, J.L., Fernandez-Montesinos, R., Gonzalez-Rey, E., et al. (2006). Protective role for plasmid DNA-mediated VIP gene transfer in non-obese diabetic mice. In Vip, Pacap, and Related Peptides: From Gene to Therapy. H. Vaudry and M. Laburthe, eds. (Blackwell/New York Academy of Sciences, Boston, MA) pp. 337-341. (Pubitemid 44126665)
23. Holmgren, L., Ambrosino, E., Birot, O., et al. (2006). A DNA vaccine targeting angiomotin inhibits angiogenesis and suppresses tumor growth. Proc. Natl. Acad. Sci. U.S.A. 103, 9208-9213. (Pubitemid 43902557)
24. Ichinose, K., Maeshima, Y., Yamamoto, Y., et al. (2005). Antiangiogenic endostatin peptide ameliorates renal alterations in the early stage of a type 1 diabetic nephropathy model. Diabetes 54, 2891-2903. (Pubitemid 41401084)
25. Kanamori, H., Matsubara, T., Mima, A., et al. (2007). Inhibition of MCP-1/CCR2 pathway ameliorates the development of diabetic nephropathy. Biochem. Biophys. Res. Commun. 360, 772-777. (Pubitemid 47077388)
26. Kanesaki, Y., Suzuki, D., Uehara, G., et al. (2005). Vascular endothelial growth factor gene expression is correlated with glomerular neovascularization in human diabetic nephropathy. Am. J. Kidney Dis. 45, 288-294. (Pubitemid 40431054)
27. Kaya, Z., Leib, C., Werfel, S., et al. (2011). Comparison of IL-10 and MCP-1-7ND gene transfer with AAV9 vectors for protection from murine autoimmune myocarditis. Cardiovasc. Res. 91, 116-123.
28. Kim, N.H., Kim, K.B., Kim, D.L., et al. (2004). Plasma and urinary vascular endothelial growth factor and diabetic nephropathy in type 2 diabetes mellitus. Diabet. Med. 21, 545-551. (Pubitemid 38746272)
29. Koga, M., Kai, H., Egami, K., et al. (2008). Mutant MCP-1 therapy inhibits tumor angiogenesis and growth of malignant melanoma in mice. Biochem. Biophys. Res. Commun. 365, 279-284. (Pubitemid 350137285)
30. Lewis, A., Steadman, R., Manley, P., et al. (2008). Diabetic nephropathy, inflammation, hyaluronan and interstitial fibrosis. Histol. Histopathol. 23, 731-739. (Pubitemid 351552358)
31. Lowrie, D.B., Tascon, R.E., Bonato, V.L.D, et al. (1999). Therapy of tuberculosis in mice by DNA vaccination. Nature 400, 269-271. (Pubitemid 29334142)
32. Maruyama, H., Sugawa, M., Moriguchi, Y., et al. (2000). Continuous erythropoietin delivery by muscle-targeted gene transfer using in vivo electroporation. Hum. Gene Ther. 11, 429-437. (Pubitemid 30101952)
33. Miyata, T., and de Strihou, C.V. (2009). Translation of basic science into clinical medicine: novel targets for diabetic nephropathy. Nephrol. Dial. Transplant. 24, 1373-1377.
34. Mu, W., Long, D.A., Ouyang, X., et al. (2009). Angiostatin overexpression is associated with an improvement in chronic kidney injury by an anti-inflammatory mechanism. Am. J. Physiol. Renal Physiol. 296, F145-F152.
35. Nakagawa, T., Kosugi, T., Haneda, M., et al. (2009). Abnormal angiogenesis in diabetic nephropathy. Diabetes 58, 1471-1478.
36. Nasu, T., Maeshima, Y., Kinomura, M., et al. (2009). Vasohibin-1, a negative feedback regulator of angiogenesis, ameliorates renal alterations in a mouse model of diabetic nephropathy. Diabetes 58, 2365-2375.
37. Ohga, S., Shikata, K., Yozai, K., et al. (2007). Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-jB activation. Am. J. Physiol. Renal Physiol. 292, F1141-F1150. (Pubitemid 46578056)
38. Ohkawa, H., Ohishi, N., and Yagi, K. (1979). Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 95, 351-358. (Pubitemid 9194347)
39. Prud'homme, G.J. (2005) DNA vaccination against tumors. J. Gene Med. 7, 3-17.
40. Raptis, A.E., and Viberti, G. (2001). Pathogenesis of diabetic nephropathy. Exp. Clin. Endocrinol. Diabetes 109, S424-S437. (Pubitemid 32577594)
41. Rivero, A., Mora, C., Muros, M., et al. (2009). Pathogenic perspectives for the role of inflammation in diabetic nephropathy. Clin. Sci. 116, 479-492.
42. Saito, K., Lehar, M., Li, Z.B., et al. (2006). High efficiency gene delivery into laryngeal muscle with bidirectional electroporation. Otolaryngol. Head Neck Surg. 135, 209-214. (Pubitemid 44160637)
43. San-Gil, F., Schier, G.M., Moses, R.G., and Gan, I.E. (1985). Improved estimation of fructosamine, as a measure of glycated serum protein, with the Technicon RA-1000 analyzer. Clin. Chem. 31, 2005-2006. (Pubitemid 16052437)
44. Saraheimo, M., Teppo, A.M., Forsblom, C., et al. (2003). Diabetic nephropathy is associated with low-grade inflammation in type 1 diabetic patients. Diabetologia 46, 1402-1407. (Pubitemid 37297211)
45. Schneider, J., Gilbert, S.C., Blanchard, T.J., et al. (1998). Enhanced immunogenicity for CD8 + T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat. Med. 4, 397-402. (Pubitemid 28212753)
46. Shah, I.M., Mackay, S.P., and McKay, G.A. (2009). Therapeutic strategies in the treatment of diabetic nephropathy-a translational medicine approach. Curr. Med. Chem. 16, 997-1016.
47. Sisson, T.H., Hattori, N., Xu, Y., and Simon, R.H. (1999). Treatment of bleomycin-induced pulmonary fibrosis by transfer of urokinase-type plasminogen activator genes. Hum. Gene Ther. 10, 2315-2323. (Pubitemid 29459842)
48. Stehouwer, C.D.A., Gall, M.A., Twisk, J.W.R., et al. (2002). Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes 51, 1157-1165. (Pubitemid 34438363)
49. Tashiro, K., Koyanagi, I., Saitoh, A., et al. (2002). Urinary levels of monocyte chemoattractant protein-1 (MCP-1) and interleukin-8 (IL-8), and renal injuries in patients with type 2 diabetic nephropathy. J. Clin. Lab. Anal. 16, 1-4.
50. Tesch, G.H. (2008). MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy. Am. J. Physiol. Renal Physiol. 294, F697-F701.
51. Tesch, G.H., and Allen, T.J. (2007). Rodent models of streptozotocin-induced diabetic nephropathy. Nephrology (Carlton) 12, 261-266. (Pubitemid 46718209)
52. Tisch, R., Wang, B., Weaver, D.J., et al. (2001). Antigen-specific mediated suppression of b cell autoimmunity by plasmid DNA vaccination. J. Immunol. 166, 2122-2132. (Pubitemid 32114703)
53. Troyanovsky, B., Levchenko, T., Mansson, G., et al. (2001). Angiomotin: an angiostatin binding protein that regulates endothelial cell migration and tube formation. J. Cell Biol. 152, 1247-1254. (Pubitemid 34280181)
54. Usui, H., Shikata, K., Matsuda, M., et al. (2003). HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats. Nephrol. Dial. Transplant. 18, 265-272. (Pubitemid 36181675)
55. Utimura, R., Fujihara, C.K., Mattar, A.L., et al. (2003). Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes. Kidney Int. 63, 209-216. (Pubitemid 35463923)
56. van den Engel, N.K., Haack, M.A., Martin, S., and Kolb, H. (2002). Oral DNA vaccination with a plasmid encoding soluble ICAM-1 modulates cytokine expression profiles in nonobese diabetic mice. J. Mol. Med. (Berl.) 80, 301-308. (Pubitemid 34507890)
57. Vlassara, H., Torreggiani, M., Post, J.B., et al. (2009). Role of oxidants/inflammation in declining renal function in chronic kidney disease and normal aging. Kidney Int. 76, S3-S11.
58. Volk, T., Hensel, M., Schuster, H., Kox, W.J. (2000). Secretion of MCP-1 and IL-6 by cytokine stimulated production of reactive oxygen species in endothelial cells. Mol. Cell. Biochem. 206, 105-112. (Pubitemid 30246512)
59. Wada, T., Furuichi, K., Sakai, N., et al. (2000). Up-regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy. Kidney Int. 58, 1492-1499.
60. Wada, T., Furuichi, K., Sakai, N., et al. (2004). Gene therapy via blockade of monocyte chemoattractant protein-1 for renal fibrosis. J. Am. Soc. Nephrol. 15, 940-948. (Pubitemid 38375313)
61. Wang, H., Zhang, Z.X., Chu, W., et al. (2005). Molecular screening and association analyses of the interleukin 6 receptor gene variants with type 2 diabetes, diabetic nephropathy, and insulin sensitivity. J. Clin. Endocrinol. Metab. 90, 1123-1129. (Pubitemid 40279243)
62. Wang, J.J., Zhang, S.X., Mott, R., et al. (2008). Anti-inflammatory effects of pigment epithelium-derived factor in diabetic nephropathy. Am. J. Physiol. Renal Physiol. 294, F1166-F1173.
63. Xu, Z.G., Lanting, L., Vaziri, N.D., et al. (2005). Upregulation of angiotensin II type 1 receptor, inflammatory mediators, and enzymes of arachidonate metabolism in obese Zucker rat kidney: reversal by angiotensin II type 1 receptor blockade. Circulation 111, 1962-1969. (Pubitemid 40570216)
64. Yamamoto, Y., Maeshima, Y., Kitayama, H., et al. (2004). Tumstatin peptide, an inhibitor of angiogenesis, prevents glomerular hypertrophy in the early stage of diabetic nephropathy. Diabetes 53, 1831-1840. (Pubitemid 38857042)
65. Yang, B.M., Cross, D.F., Ollerenshaw, M., et al. (2003). Polymorphisms of the vascular endothelial growth factor and susceptibility to diabetic microvascular complications in patients with type I diabetes mellitus. J. Diabetes Complications 17, 1-6. (Pubitemid 36042784)
66. Yozai, K., Shikata, K., Sasaki, M., et al. (2005). Methotrexate prevents renal injury in experimental diabetic rats via antiinflammatory actions. J. Am. Soc. Nephrol. 16, 3326-3338. (Pubitemid 46179336)
67. Zent, R., and Pozzi, A. (2006). Antiangiogenic therapy in diabetic nephropathy. J. Am. Soc. Nephrol. 17, 325-327.
68. Zent, R., and Pozzi, A. (2007). Angiogenesis in diabetic nephropathy. Semin. Nephrol. 27, 161-171. (Pubitemid 46566340)